ST Pharm is a subsidiary company of Dong-A Socio Group, Korea’s top pharmaceutical company with a history of 80 years. ST Pharm operates fully integrated services, including CRO and CDMO business, which allows one-stop service from pre-clinical stage to commercialisation. The main business of ST Pharm is API CDMO business and producing now more than 40 pipelines of excellent quality APIs through our ample knowledge and accumulated know-hows. The expansion of production capabilities in the production of oligonucleotides became a new growth engine for the future. In particular, the establishment of Oligonucleotide Plant in 2018 has secured our place in the Global Top 3 oligonucleotide production company. In 2020, ST Pharm has launched new manufacturing business for mRNA vaccines and therapeutics and the decision has been made to compete for preoccupancy of rapidly growing global mRNA vaccine markets.